WO1997045406A1 - 3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones - Google Patents

3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones Download PDF

Info

Publication number
WO1997045406A1
WO1997045406A1 PCT/US1997/009666 US9709666W WO9745406A1 WO 1997045406 A1 WO1997045406 A1 WO 1997045406A1 US 9709666 W US9709666 W US 9709666W WO 9745406 A1 WO9745406 A1 WO 9745406A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
group
alkyl
aryl
compound
Prior art date
Application number
PCT/US1997/009666
Other languages
French (fr)
Inventor
Guang-Zhong Wu
Xing Chen
Yee-Shing Wong
Doris P. Schumacher
Martin Steinman
Original Assignee
Schering Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corporation filed Critical Schering Corporation
Priority to AT97928831T priority Critical patent/ATE226191T1/en
Priority to JP54307797A priority patent/JP3155759B2/en
Priority to DK97928831T priority patent/DK0906278T3/en
Priority to DE69716426T priority patent/DE69716426T2/en
Priority to EP97928831A priority patent/EP0906278B1/en
Priority to AU32994/97A priority patent/AU3299497A/en
Priority to CA002255662A priority patent/CA2255662C/en
Publication of WO1997045406A1 publication Critical patent/WO1997045406A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D205/00Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics

Definitions

  • This invention provides an improved process for producing azetidinones useful as hypocholesterolemic agents, as disclosed in co- owned, copending PCT Publication WO 95/08532, which is equivalent to U.S. Serial No. 08/617,751 , filed March 18, 1996, the disclosure of which is hereby incorporated by reference. More particularly, this invention provides the steps of producing an azetidinone represented by the formula I.
  • This invention provides a process for producing a compound of the formula:
  • Ri , R2 and R3 are independently selected from the group consisting of: (a) H; (b) halo;
  • R5 is selected from the group consisting of H, C1 to C-6 alkyl, aryl, aralkyl, heteroaryl, C2 to CQ alkynyl, C3 to C7 cycloalkyl, C3 to C7 cycloalkenyl and -C(O)R6;
  • Re is selected from the group consisting of Ci to C ⁇ alkyl, aryl and -OR7; and R7 is Ci to C ⁇ alkyl or aryl;
  • Re is selected from the group consisting of Ci to CQ alkyl, aryl, heteroaryl, aralkyl, cycloalkyl, -ORg and -N(R ⁇ o)2
  • R9 is selected from the group consisting of Ci to C& alkyl and aryl
  • each R10 is independently selected from the group consisting of H, Ci to C ⁇ alkyl and aryl.
  • this process is useful for preparing 1 -(4-fluoro- phenyl)-3(R)-[3(S)-hydroxy-3-(4-fluorophenyl)propyl]-4(S)-(4- fluorophenyl)-2-azetidinone.
  • this process comprises reaction of a ⁇ -lactone and an imine to form a ⁇ -lactam, followed by a chiral reduction.
  • this invention is directed to a process for preparing a compound of formula I
  • R-i , R2 and R3 are as defined above, comprising (a) reacting lactone of formula II
  • lower alkyl means straight or branched alkyl chains of 1 to 6 carbon atoms. Alternatively, the number of carbon atoms may be specified. Thus, “Ci to C ⁇ alkyl” means straight or branched alkyl chains of 1 to 6 carbon atoms.
  • Lower alkoxy refers to alkoxy groups having 1 to 6 carbon atoms. Alternatively, the number of carbon atoms may be specified. Thus, “Ci to C ⁇ alkoxy” means straight or branched alkoxy chains of 1 to 6 carbon atoms.
  • alkenyl means straight or branched carbon chains having one or more double bonds in the chain, conjugated or unconjugated, and alkadienyl refers to chains having two double bonds in the chain. Alternatively, the number of carbon atoms may be specified. Thus, “Ci to C ⁇ alkenyl” means straight or branched alkenyl chains of 1 to 6 carbon atoms. “Alkynyl” means straight or branched carbon chains having one or more triple bonds in the chain. Alternatively, the number of carbon atoms may be specified. Thus, “Ci to Ce alkynyl” means straight or branched alkynyl chains of 1 to 6 carbon atoms. Where an alkyl, alkenyl or alkynyl chain joins two other variables and is therefore bivalent, the terms alkylene, alkenylene and alkynylene are used.
  • Aryl (including substituted aryl) means a carbocyclic group containing from 6 to 15 carbon atoms and having at least one aromatic ring (e.g. aryl is a phenyl ring), with all available substitutable carbon atoms of the carbocyclic group being intended as possible points of attachment, said carbocyclic group being optionally substituted by 1 to 3 substituents selected from the group consisting of halo, alkyl, hydroxy, phenoxy, CF3, amino, alkylamino, dialkylamino and -NO2.
  • Alkyl means an alkyl group as defined above, in which an aryl group as defined above is substituted for one of the alkyl H atoms, e.g., benzyl, 4-nitro-benzyl' 4-methoxy benzyl and 4-chlorobenzyl.
  • Acid means an organic acid such as p-toluene sulfonic acid, trifluoroacetic acid or trifluoromethane sulfonic acid.
  • acid means an inorganic acid such as sulfuric acid, hydrochloric acid or phosphonic acid.
  • Haldrogenation catalyst means a transition metal or its salt such as Pd/C, Pt/C, Raney nickel, Rh/C, Ru/C, PdO, PtO or (PPh 3 ) 3 RhCI.
  • Cycloalkenyl mean a cycloalkane of 4 to 10 carbon atoms with one or more double bonds in the ring.
  • Bn means benzyl.
  • BnO means benzyloxy.
  • Cycloalkyl means a saturated carbon ring of 3 to 6 carbon atoms
  • cycloalkylene refers to a corresponding bivalent ring, wherein the points of attachment to other groups include all positional isomers. Alternatively, the number of carbon atoms may be specified. Thus, “C3 to C ⁇ cycloalkyl” means a saturated carbon ring of 3 to 6 carbon atoms.
  • Halogeno or "hal” or “halogen” refers to fluorine, chlorine, bromine or iodine radicals.
  • Heteroaryl means a 5- or 6-membered aromatic ring comprising 1 or 2 hetero atoms selected from the groups consisting of nitrogen and oxygen, for example pyridyl, pyrimidyl, imidazolyl, pyrrolyl, furanyl and oxazolyl. All positional isomers for a given heteroaryl group as defined herein are contemplated, for example 2-pyridyl, 3-pyridyl and 4-pyridyl.
  • Heteroaryl also means benzofused heteroaryl radicals formed by the bonding of a benzene radical to adjacent carbon atoms on a heteroaryl ring as defined above; examples are indolyl, quinolyl, quinazolinyl, quinoxalinyl, indazolyl, benzoxazolyl, benzothienyl and benzofuranyl.
  • Ph means phenyl.
  • Suitable inert organic solvent means any organic solvent or combination of solvents that is unreactive in the reaction being conducted and is a solvent for the reactants.
  • solvents used in the various reactions of this invention are identified in the discussion of reaction schemes and in the examples.
  • Typical suitable solvents are halogenated compounds such as chloroform or dichloromethane; heterocyclic compounds such as tetrahydrofuran (THF); 1 ,3-dimethyl- 3,4,5,6-tetrahydro-2(1 H)-pyrimidinone (DMPU), dimethylformamide (DMF); dimethylsulf oxide (DMSO), lower alkanols (CrC ⁇ branched or straight chain alkanols) such as methanol, acetonitrile and carbocyclic aromatics such as toluene.
  • THF tetrahydrofuran
  • DMPU 1 ,3-dimethyl- 3,4,5,6-tetrahydro-2(1 H)-pyrimidinone
  • Lewis acid means an acid such as BF3 » etherate, TiCU or AICI3.
  • the process of this invention comprises reaction of a ⁇ -lactam and an imine to form a ⁇ -lactam, followed by a chiral reduction according to Reaction Scheme A just below.
  • Reaction Scheme A Reaction Scheme A
  • R-i, R2 or R3 is a benzyloxy or alkoxy group
  • converting said benzyloxy or alkoxy group to a hydroxy group for example conducting a debenzylation reaction with a hydrogenating agent such as Pd/C/NH3HC02H or converting an alkoxy group to a hydroxy group by treatment with a Lewis acid to obtain a compound of formula I.
  • step (a) of Reaction Scheme A the lactone II is treated in a strong base such as lithium diisopropylamide (LDA) with an imine of formula III under a dry atmosphere at a temperature in the range of about -15° to about -35°C in a suitable inert organic solvent, e.g., DMPU, to produce a ⁇ -lactam of formula IV.
  • a strong base such as lithium diisopropylamide (LDA)
  • imine of formula III under a dry atmosphere at a temperature in the range of about -15° to about -35°C in a suitable inert organic solvent, e.g., DMPU
  • the reaction can be quenched by an acid such as acetic acid, and a trans ⁇ -iactam of formula IV can be recovered by extraction followed by crystallization. Because trans ⁇ -lactam cyclizes faster than cis ⁇ -lactam, formation of a trans isomer is favored.
  • This cyclization can be greatly accelerated by addition of additives such as LiCI or LiBr (in a solvent such as DMF) resulting in further selectivity of trans ⁇ -lactam formation.
  • a crystallization step at this stage further improves the ratio of trans to cis ⁇ -lactam to 95:5.
  • use of a weaker coordination metal favors the formation of a trans ⁇ -lactam of formula IV.
  • the use of sodium lithium hexamethyldisilyl amide (LiHMDA) as a base favors the formation of a trans ⁇ -lactam of formula IV as opposed to the cis isomer, and is preferred as opposed to Et2Zn/LDA or LiN(Pr-i)2.
  • a lower temperature favors the formation of a trans ⁇ -lactam of formula IV, as opposed to the cis isomer; and thus -35°C, is preferred over -25°C or -15°C.
  • a ⁇ -lactam of formula IV is oxidized by treatment with an oxidizing agent such as Nal ⁇ 4 in a mixture of solvents such as THF and water at a temperature between about 10°C and 25°C, with about 10°C to about 15°C being preferred.
  • the ratio of the oxidizing agent, Nal ⁇ 4, to diol is as follows: if the diol is present at 1.0 equivalent, then the Nal ⁇ 4 is present at 1.0-2.0 equivalents, with 1.5 equivalent being preferred.
  • the organic solvent for the reaction is a polar aprotic solvent such as acetronitrile or THF.
  • the reaction is quenched by adding the reaction mixture to ice water.
  • the resulting aldehyde of formula V is extracted and concentrated for use in the next step of the process.
  • step (c) an aldehyde of formula V is reacted with the enolether of the formula E in an aprotic anhydrous organic solvent such as toluene in the presence of a Lewis acid such as BF3*etherate at a temperature in the range of about -78°C to about -20°C, with about -40°C to about -20°C being preferred.
  • a Lewis acid such as BF3*etherate
  • the resulting aldol reaction can be quenched, for example with a mixture of NaHC03, t-BuOMe and hydrogen peroxide.
  • the ratio of the ⁇ -lactam and the enolether can be as follows: if the ⁇ -lactam is present at 1.0 equivalent, then the enolether can be present at 0.9 to 1.2 equivalent with 1.0 equivalent being most preferred.
  • the ratio of the ⁇ -lactam and BF3»etherate can be as follows: if the ⁇ -lactam is present at 1.0 equivalents, then BF 3 »etherate can be present at 1.0 to 1.5 equivalent, with 1.0 to 1.2 equivalent being preferred.
  • the resulting solution containing aldol product is extracted and concentrated for the dehydration step which involves treatment with molecular sieves and an organic acid such as p-toluene sulfonic acid monohydrate.
  • an organic acid such as p-toluene sulfonic acid monohydrate.
  • the aldol product is present at 1.0 equivalent, then the p-toluene sulfonic acid monohydrate can be present at 0.4 to 0.8 equivalent, with 0.5 to 0.6 equivalent being preferred.
  • the solvents which may be employed in this reaction include toluene, t-butyl methyl ether (t-BuOMe), or benzene.
  • the molecular sieves which are used in this reaction are 3A or 4A and are present in the reaction at 100% to 200% weight/weight as compared to the aldol compound.
  • the reaction temperature is about 35°C to about 100°C, with the range of about 45°C to about 60°C being preferred.
  • the resulting compound of formula VI is filtered and concentrated for use in the next step of this process. It will be appreciated that a compound of formula VI is formed with cis and trans stereochemistry. That is,
  • step (d) the compound of formula VI is hydrogenated by treatment with a hydrogenating agent such as (Ph 3 P)3RhCI/H2 under a hydrogen atmosphere in an organic solvent such as a mixture of ethyl acetate (EtOAc) and CH3OH; CH2CI2; toluene; or benzene.
  • a hydrogenating agent such as (Ph 3 P)3RhCI/H2 under a hydrogen atmosphere in an organic solvent such as a mixture of ethyl acetate (EtOAc) and CH3OH; CH2CI2; toluene; or benzene.
  • EtOAc ethyl acetate
  • the ratio of hydrogenating agent to the compound of formula VI is as follows: if the compound of formula VI is present at 1 mol %, then the hydrogenating agent is present at 0.1 to 10 mol %, with 0.3 mol % being preferred.
  • the hydrogen atmosphere is present at 5 to 100 psi, with 40 o 60
  • step (e) the compound of formula VII is chirally reduced by reaction in an anhydrous organic solvent such as CH2CI2, THF or toluene, in the presence of a borane, such as BH3 » (CHa)2S or borane- THF complex, and a chiral reduction catalyst such as
  • the ratio of the compound of formula VII to the chiral reduction catalyst is as follows: if the compound of formula VII is present at 1.0 equivalent, then the catalyst is present in a range of about 5 mol % to 100 mol %, with 5 mol % to 10 mol % being preferred. If the compound of formula VII is present at 1.0 equivalent, then the borane (e.g., BH3 » Me2S) is present at 0.7 to 1.0 equivalent, with 0.7 to 0.8 equivalent being most preferred.
  • the borane e.g., BH3 » Me2S
  • the protected compound of formula I is debenzylated by treatment with a hydrogenating agent such as Pd/C/HC ⁇ 2NH4 under a hydrogen atmosphere: the concentration of Pd/C is 5% to 20% w/w, with 10-15% w/w being preferred.
  • the ratio of compound of formula I to Pd/C used is 1.0 equivalent of compound of formula I to 2.0 to 5.0 equivalents of Pd/C, with 3.0 to 4.0 equivalent of Pd/C being preferred.
  • hydrogen gas is used in the ranges from 5 psi (pound per square inch) to 100 psi with 20 to 40 psi being preferred.
  • the solvents which can be employed at this stage of the reaction include CH3OH, ethanol and i-propanol.
  • Alkoxy groups can be converted to hydroxy groups by well-known methods, for example by treatment with a Lewis acid.
  • a reactive substituent at any of R-i, R2 or R3, such as hydroxy or amino can be protected with a suitable protecting group during the claimed process and said protecting group can be removed after the desired compound of formula I is obtained.
  • the corresponding cis product is also formed.
  • the cis product is present at this stage of the process in an amount of 5% as compared to the trans product.
  • the cis product may now be purged out by crystallization.
  • the compound of formula VII' is chirally reduced as described above, in the presence of a chiral reduction catalyst to obtain the reduced compound of formula I'
  • the compound of formula I' is debenzylated by treatment with a hydrogenating agent such as Pd/C/HCO2NH4 under a hydrogen atmosphere to obtain a compound of formula I"
  • the compound of formula VI' can be chirally reduced to the compound of formula XI' which can then be hydrogenated to obtain the compound of formula I"
  • a compound of formula VI" may be converted by the Noyori reduction, i.e. using the catalyst (R)- Ru(BINAP)Cl2]2-NEt3. to obtain the compound of formula I'".
  • a compound of formula VI' can be reduced by this method to obtain a compound of formula I".
  • the starting material of formula I! is known, and may be prepared from s-malic acid of the formula
  • the ⁇ -lactone of formula II may be obtained from glucose as described in U.S. Patent 5,292,939, Hollingsworth, which is hereby incorporated by reference.
  • An imine of formula III' may be prepared by reacting 4-benzyloxy benzaldehyde with 4-fluoroaniline in a polar organic solvent such as isopropanol at about room temperature.
  • Other imines of the formula III may be prepared in a similar manner, by reacting the appropriate benzaldehyde derivatives and the appropriate aniline derivatives in isopropanol at room temperature for 2 to 3 hours and filtering the reaction mixture to give the product as a solid.
  • An enolether of the formula E' may be prepared by reacting 4-fluoro-acetophenone (which is a -known compound or may be prepared by known methods) in a solution of lithium diisopropylamide in a polar organic solvent such THF at a temperature in the range of about -30°C to about -35°C, with quenching by addition of M ⁇ 3SiCI, concentration and distillation to obtain the enolether product.
  • Other enolethers of formula E may be prepared in a similar manner.
  • the reaction mixture was poured slowly into a 10-liter extractor containing 2 liters of 3 N HCI, 1 liter ice and 2.5 liters of EtOAc. The mixture was stirred for 15 min. and separated into layers. The aqueous layer was extracted with 1.0 liter and then with 0.5 liter of EtOAc. The combined organic layers were washed with 4 X 2 liter brine, concentrated, and 250 mL toluene was added to crystallize the trans lactam 4. The solid was filtered and dried at 50°C to give 85.5 g (64% yield) lactam 4. Mp: 119-120°C.
  • This quench solution was then cooled to 0°C with an ice bath.
  • the aldol mixture was added dropwise into the quench solution at 0°C.
  • the quenched mixture was allowed to warm to 15 to 20°C and the layers were separated.
  • the aqueous layer was extracted with 1 liter toluene.
  • the combined organic layer was washed with 2 X 500 mL and concentrated to about 1 liter for dehydration.
  • reaction also could be carried out as follows: A mixture of 1 g of compound 6A in 10 mL of EtOAc, 1 mL of water, and 0.5 (w/w)% of Pd/C (wet) was shaken under 25 psi of H2 for ca. 4 hrs. The mixture was filtered through celite and washed with toluene. Concentration gave compound 8.
  • the chiral catalyst was made following the standard procedure: trimethylboroxine (28 mg, 0.22 mmol) was added into a solution of diphenylprolinol (75 mg, 0.3 mmol) in toluene (5ml) and the resultant solution was heated until refluxing. Toluene was distilled and another 5 ml of toluene was added and distilled out. The residue was used directly in the following reaction. To a 50 mL oven-dried flask with a magnetic stirrer were added
  • the crude compound 6A generated from dehydration step from 80 mmol of aldol condensation product, was dissolved in 120 ml of CH2CI2 to which 2.2g (2.4 mmol) of the catalyst was added. The mixture was subjected hydrogenation at 60 psi for 18 hr. Concentration of the reaction gave a residue of the product, which was separated by column with hexane and EtOAc (90:10) to give 27.5 g pure product, 71 % from aldol condensation product as starting material.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

The invention relates to a process for producing a compound of formula (I) wherein R1, R2 and R3 are as defined in the specification, which comprises reacting a lactone with an imine to obtain a chiral diol of formula (IV) oxidizing the diol, condensing the resultant aldehyde with an enolether, hydrogenating the product, and chirally catalytically reducing the resultant ketone.

Description

3-HYDROXY GAMMA-LACTONE BASED
ENANTIOSELECTIVE SYNTHESIS OF AZETIDINONES
BACKGROUND OF THE INVENTION This invention provides an improved process for producing azetidinones useful as hypocholesterolemic agents, as disclosed in co- owned, copending PCT Publication WO 95/08532, which is equivalent to U.S. Serial No. 08/617,751 , filed March 18, 1996, the disclosure of which is hereby incorporated by reference. More particularly, this invention provides the steps of producing an azetidinone represented by the formula I.
SUMMARY OF THE INVENTION
This invention provides a process for producing a compound of the formula:
Figure imgf000003_0001
wherein:
Ri , R2 and R3 are independently selected from the group consisting of: (a) H; (b) halo;
(c) -OR5, wherein: R5 is selected from the group consisting of H, C1 to C-6 alkyl, aryl, aralkyl, heteroaryl, C2 to CQ alkynyl, C3 to C7 cycloalkyl, C3 to C7 cycloalkenyl and -C(O)R6; Re is selected from the group consisting of Ci to Cβ alkyl, aryl and -OR7; and R7 is Ci to Cβ alkyl or aryl; and
(d) -C(0)Rβ, wherein: Re is selected from the group consisting of Ci to CQ alkyl, aryl, heteroaryl, aralkyl, cycloalkyl, -ORg and -N(Rιo)2; R9 is selected from the group consisting of Ci to C& alkyl and aryl; and each R10 is independently selected from the group consisting of H, Ci to Cβ alkyl and aryl.
In particular, this process is useful for preparing 1 -(4-fluoro- phenyl)-3(R)-[3(S)-hydroxy-3-(4-fluorophenyl)propyl]-4(S)-(4- fluorophenyl)-2-azetidinone.
In general, this process comprises reaction of a γ-lactone and an imine to form a β-lactam, followed by a chiral reduction. In particular, this invention is directed to a process for preparing a compound of formula I
Figure imgf000004_0001
wherein R-i , R2 and R3 are as defined above, comprising (a) reacting lactone of formula II
Figure imgf000004_0002
with an imine of formula III
Figure imgf000004_0003
in the presence of a base, and optionally in the presence of a cyclization promoter, to obtain a chiral diol of formula IV
Figure imgf000005_0001
(b) oxidizing the chiral diol of formula IV to the corresponding aldehyde of formula V
Figure imgf000005_0002
(c) condensing the aldehyde of formula V with an enolether of the formula E
Figure imgf000005_0003
followed by dehydration to obtain a compound of formula VI
Figure imgf000005_0004
(d) hydrogenating a compound of formula VI to form a compound of formula VII
Figure imgf000005_0005
(e) conducting a chiral catalytic reduction of the compound of formula VII to obtain a compound of formula I; (f) optionally, when any of R-i, R2 or R3 is a benzyloxy or alkoxy group, converting said benzyloxy or alkoxy group to a hydroxy group to obtain a compound of formula I.
Also claimed are the following processes for preparing intermediates:
The process of reacting a lactone of formula II with an imine of formula III in the presence of a base and optionally in the presence of a cyclization promoter to obtain a chiral diol of formula IV.
The process of oxidizing a chiral diol of formula IV to obtain an aldehyde of formula V.
The process of condensing an aldehyde of formula V with an enolether of formula E, followed by dehydration to obtain a compound of formula VI.
The process of hydrogenating a compound of formula VI to obtain a ketone of formula VII.
The process of hydrogentating a compound of formula VI"
Figure imgf000006_0001
to obtain a compound of formula X
Figure imgf000006_0002
The process of chirally reducing the keto group in the compound of formula VI" to obtain a compound of formula XI
Figure imgf000006_0003
Also claimed are the intermediates of formulas IV and VI.
DETAILED DESCRIPTION
As used herein the term "lower alkyl" means straight or branched alkyl chains of 1 to 6 carbon atoms. Alternatively, the number of carbon atoms may be specified. Thus, "Ci to Cε alkyl" means straight or branched alkyl chains of 1 to 6 carbon atoms. "Lower alkoxy" refers to alkoxy groups having 1 to 6 carbon atoms. Alternatively, the number of carbon atoms may be specified. Thus, "Ci to Cβ alkoxy" means straight or branched alkoxy chains of 1 to 6 carbon atoms.
"Alkenyl" means straight or branched carbon chains having one or more double bonds in the chain, conjugated or unconjugated, and alkadienyl refers to chains having two double bonds in the chain. Alternatively, the number of carbon atoms may be specified. Thus, "Ci to Cβ alkenyl" means straight or branched alkenyl chains of 1 to 6 carbon atoms. "Alkynyl" means straight or branched carbon chains having one or more triple bonds in the chain. Alternatively, the number of carbon atoms may be specified. Thus, "Ci to Ce alkynyl" means straight or branched alkynyl chains of 1 to 6 carbon atoms. Where an alkyl, alkenyl or alkynyl chain joins two other variables and is therefore bivalent, the terms alkylene, alkenylene and alkynylene are used.
"Aryl" (including substituted aryl) means a carbocyclic group containing from 6 to 15 carbon atoms and having at least one aromatic ring (e.g. aryl is a phenyl ring), with all available substitutable carbon atoms of the carbocyclic group being intended as possible points of attachment, said carbocyclic group being optionally substituted by 1 to 3 substituents selected from the group consisting of halo, alkyl, hydroxy, phenoxy, CF3, amino, alkylamino, dialkylamino and -NO2. "Aralkyl" means an alkyl group as defined above, in which an aryl group as defined above is substituted for one of the alkyl H atoms, e.g., benzyl, 4-nitro-benzyl' 4-methoxy benzyl and 4-chlorobenzyl.
"Acid" means an organic acid such as p-toluene sulfonic acid, trifluoroacetic acid or trifluoromethane sulfonic acid. Alternatively "acid" means an inorganic acid such as sulfuric acid, hydrochloric acid or phosphonic acid.
"Hydrogenation catalyst" means a transition metal or its salt such as Pd/C, Pt/C, Raney nickel, Rh/C, Ru/C, PdO, PtO or (PPh3)3RhCI. "Cycloalkenyl" mean a cycloalkane of 4 to 10 carbon atoms with one or more double bonds in the ring.
"Bn" means benzyl. "BnO" means benzyloxy.
"Cycloalkyl" means a saturated carbon ring of 3 to 6 carbon atoms, while "cycloalkylene" refers to a corresponding bivalent ring, wherein the points of attachment to other groups include all positional isomers. Alternatively, the number of carbon atoms may be specified. Thus, "C3 to Cβ cycloalkyl" means a saturated carbon ring of 3 to 6 carbon atoms.
"Halogeno" or "hal" or "halogen" refers to fluorine, chlorine, bromine or iodine radicals.
"Heteroaryl" means a 5- or 6-membered aromatic ring comprising 1 or 2 hetero atoms selected from the groups consisting of nitrogen and oxygen, for example pyridyl, pyrimidyl, imidazolyl, pyrrolyl, furanyl and oxazolyl. All positional isomers for a given heteroaryl group as defined herein are contemplated, for example 2-pyridyl, 3-pyridyl and 4-pyridyl. Heteroaryl also means benzofused heteroaryl radicals formed by the bonding of a benzene radical to adjacent carbon atoms on a heteroaryl ring as defined above; examples are indolyl, quinolyl, quinazolinyl, quinoxalinyl, indazolyl, benzoxazolyl, benzothienyl and benzofuranyl. "Ph" means phenyl.
"Suitable inert organic solvent" means any organic solvent or combination of solvents that is unreactive in the reaction being conducted and is a solvent for the reactants. Such solvents used in the various reactions of this invention are identified in the discussion of reaction schemes and in the examples. Typical suitable solvents are halogenated compounds such as chloroform or dichloromethane; heterocyclic compounds such as tetrahydrofuran (THF); 1 ,3-dimethyl- 3,4,5,6-tetrahydro-2(1 H)-pyrimidinone (DMPU), dimethylformamide (DMF); dimethylsulf oxide (DMSO), lower alkanols (CrCβ branched or straight chain alkanols) such as methanol, acetonitrile and carbocyclic aromatics such as toluene.
"Lewis acid" means an acid such as BF3»etherate, TiCU or AICI3.
In one aspect, the process of this invention comprises reaction of a γ-lactam and an imine to form a β-lactam, followed by a chiral reduction according to Reaction Scheme A just below. Reaction Scheme A
Figure imgf000009_0001
This process, designated Method A, for producing compounds of
O H
& formula I, wherein the moieties ^^ and "** have trans relative stereochemistry, comprises the following steps:
(a) reacting lactone of formula II with an imine of formula Hi in the presence of a strong base and optionally in the presence of a cyclization promoter, to obtain a chiral diol of formula IV; (b) oxidizing the resulting chiral diol of formula IV to the corresponding aldehyde of formula V, for example with an oxidizing agent such as Nalθ4 or H5IO6;
(c) condensing the aldehyde of formula V with an enolether of the formula E
Figure imgf000010_0001
followed by dehydration, for example acid catalyzed dehydration, to obtain a compound of formula VI;
(d) hydrogenation of a compound of formula VI with a hydrogenation catalyst agent such as hydrogen over palladium or hydrogen and (PPh3)RhCI on carbon to form a compound of formula VII;
(e) conducting a chiral catalytic reduction of the compound of formula VII with a borane, such as BH3*(CH3)2S or borane-THF
complex, and a chiral catalyst such as
Figure imgf000010_0002
Figure imgf000010_0003
to obtain a compound of formula I;
(f) optionally, when any of R-i, R2 or R3 is a benzyloxy or alkoxy group, converting said benzyloxy or alkoxy group to a hydroxy group, for example conducting a debenzylation reaction with a hydrogenating agent such as Pd/C/NH3HC02H or converting an alkoxy group to a hydroxy group by treatment with a Lewis acid to obtain a compound of formula I.
Method A is described in more detail is as follows. In step (a) of Reaction Scheme A, the lactone II is treated in a strong base such as lithium diisopropylamide (LDA) with an imine of formula III under a dry atmosphere at a temperature in the range of about -15° to about -35°C in a suitable inert organic solvent, e.g., DMPU, to produce a β-lactam of formula IV. The reaction can be quenched by an acid such as acetic acid, and a trans β-iactam of formula IV can be recovered by extraction followed by crystallization. Because trans β-lactam cyclizes faster than cis β-lactam, formation of a trans isomer is favored. This cyclization can be greatly accelerated by addition of additives such as LiCI or LiBr (in a solvent such as DMF) resulting in further selectivity of trans β-lactam formation. A crystallization step at this stage further improves the ratio of trans to cis β-lactam to 95:5. In this reaction, use of a weaker coordination metal favors the formation of a trans β-lactam of formula IV. Thus, in this reaction, the use of sodium lithium hexamethyldisilyl amide (LiHMDA) as a base favors the formation of a trans β-lactam of formula IV as opposed to the cis isomer, and is preferred as opposed to Et2Zn/LDA or LiN(Pr-i)2. Also in this reaction, a lower temperature favors the formation of a trans β-lactam of formula IV, as opposed to the cis isomer; and thus -35°C, is preferred over -25°C or -15°C.
In step (b), a β-lactam of formula IV is oxidized by treatment with an oxidizing agent such as Nalθ4 in a mixture of solvents such as THF and water at a temperature between about 10°C and 25°C, with about 10°C to about 15°C being preferred. The ratio of the oxidizing agent, Nalθ4, to diol is as follows: if the diol is present at 1.0 equivalent, then the Nalθ4 is present at 1.0-2.0 equivalents, with 1.5 equivalent being preferred. The organic solvent for the reaction is a polar aprotic solvent such as acetronitrile or THF. The reaction is quenched by adding the reaction mixture to ice water. The resulting aldehyde of formula V is extracted and concentrated for use in the next step of the process.
In step (c), an aldehyde of formula V is reacted with the enolether of the formula E in an aprotic anhydrous organic solvent such as toluene in the presence of a Lewis acid such as BF3*etherate at a temperature in the range of about -78°C to about -20°C, with about -40°C to about -20°C being preferred. The resulting aldol reaction can be quenched, for example with a mixture of NaHC03, t-BuOMe and hydrogen peroxide. In this reaction, the ratio of the β-lactam and the enolether can be as follows: if the β-lactam is present at 1.0 equivalent, then the enolether can be present at 0.9 to 1.2 equivalent with 1.0 equivalent being most preferred. The ratio of the β-lactam and BF3»etherate can be as follows: if the β-lactam is present at 1.0 equivalents, then BF3»etherate can be present at 1.0 to 1.5 equivalent, with 1.0 to 1.2 equivalent being preferred.
The resulting solution containing aldol product is extracted and concentrated for the dehydration step which involves treatment with molecular sieves and an organic acid such as p-toluene sulfonic acid monohydrate. If the aldol product is present at 1.0 equivalent, then the p-toluene sulfonic acid monohydrate can be present at 0.4 to 0.8 equivalent, with 0.5 to 0.6 equivalent being preferred. The solvents which may be employed in this reaction include toluene, t-butyl methyl ether (t-BuOMe), or benzene. The molecular sieves which are used in this reaction are 3A or 4A and are present in the reaction at 100% to 200% weight/weight as compared to the aldol compound. The reaction temperature is about 35°C to about 100°C, with the range of about 45°C to about 60°C being preferred. The resulting compound of formula VI is filtered and concentrated for use in the next step of this process. It will be appreciated that a compound of formula VI is formed with cis and trans stereochemistry. That is,
Figure imgf000012_0001
cis and trans about the azetidinone ring as shown by the arrows in these diagrams. Obtaining the compound with the trans stereochemistry is necessary in order to get the desired final products of the invention.
In step (d), the compound of formula VI is hydrogenated by treatment with a hydrogenating agent such as (Ph3P)3RhCI/H2 under a hydrogen atmosphere in an organic solvent such as a mixture of ethyl acetate (EtOAc) and CH3OH; CH2CI2; toluene; or benzene. The ratio of hydrogenating agent to the compound of formula VI is as follows: if the compound of formula VI is present at 1 mol %, then the hydrogenating agent is present at 0.1 to 10 mol %, with 0.3 mol % being preferred. The hydrogen atmosphere is present at 5 to 100 psi, with 40 o 60 psi being preferred. The reaction is run for 10 to 30 hours, with 14 to 16 hours being preferred. After extraction and concentration, the resulting compound of formula VII is used in the next step.
In step (e), the compound of formula VII is chirally reduced by reaction in an anhydrous organic solvent such as CH2CI2, THF or toluene, in the presence of a borane, such as BH3»(CHa)2S or borane- THF complex, and a chiral reduction catalyst such as
Figure imgf000013_0001
at a temperature in the range of about -30° to about 0°C, with a range of about -20° to about -10°C being preferred. The reaction is run for about 1 to about 20 hours, with a range of about 3 to about 10 hours being preferred. The ratio of the compound of formula VII to the chiral reduction catalyst is as follows: if the compound of formula VII is present at 1.0 equivalent, then the catalyst is present in a range of about 5 mol % to 100 mol %, with 5 mol % to 10 mol % being preferred. If the compound of formula VII is present at 1.0 equivalent, then the borane (e.g., BH3»Me2S) is present at 0.7 to 1.0 equivalent, with 0.7 to 0.8 equivalent being most preferred. Concentration, extraction, and crystallization leads to the reduced compound of formula I. For compounds of formula I wherein any one of Ri , R2 or R3 is benzyloxy or alkoxy, said compounds can be converted to other compounds of formula I wherein R1 , R2 or R3 is hydroxy by methods well known in the art. This is important in the preferred process described below, wherein the desired compound of formula I has a hydroxy group at R1 , but wherein the hydroxy group must be protected during the process, preferably by a benzyl group. The protected compound of formula I is debenzylated by treatment with a hydrogenating agent such as Pd/C/HCθ2NH4 under a hydrogen atmosphere: the concentration of Pd/C is 5% to 20% w/w, with 10-15% w/w being preferred. The ratio of compound of formula I to Pd/C used is 1.0 equivalent of compound of formula I to 2.0 to 5.0 equivalents of Pd/C, with 3.0 to 4.0 equivalent of Pd/C being preferred. Alternatively, hydrogen gas is used in the ranges from 5 psi (pound per square inch) to 100 psi with 20 to 40 psi being preferred. The solvents which can be employed at this stage of the reaction include CH3OH, ethanol and i-propanol. Alkoxy groups can be converted to hydroxy groups by well-known methods, for example by treatment with a Lewis acid. Those skilled in the art will recognize that a reactive substituent at any of R-i, R2 or R3, such as hydroxy or amino, can be protected with a suitable protecting group during the claimed process and said protecting group can be removed after the desired compound of formula I is obtained. As noted above, when trans β-lactam is formed in step (a), the corresponding cis product is also formed. The cis product is present at this stage of the process in an amount of 5% as compared to the trans product. The cis product may now be purged out by crystallization. In a preferred embodiment of the invention, an imine of the formula
Figure imgf000014_0001
is used and an enoleth of the formula E'
Figure imgf000014_0002
is used. Consequently the compound of formula VI which results has the structural formula VI':
Figure imgf000014_0003
This resulting compound of formula VI' is hydrogenated as described above, the resulting in a compound of formula VII'
Figure imgf000015_0001
The compound of formula VII' is chirally reduced as described above, in the presence of a chiral reduction catalyst to obtain the reduced compound of formula I'
Figure imgf000015_0002
The compound of formula I' is debenzylated by treatment with a hydrogenating agent such as Pd/C/HCO2NH4 under a hydrogen atmosphere to obtain a compound of formula I"
Figure imgf000015_0003
Alternatively, a compound of formula VI"
may undergo a double hydrogenation step by reaction under hydrogen in the presence of a hydrogenation catalyst such as palladium on carbon to obtain a compound of formula X
Figure imgf000016_0001
The carbonyl adjacent to the R3-substituted phenyl group is then chirally reduced to obtain the corresponding compound of formula I"'
Figure imgf000016_0002
In particular, a compound of formula VI' undergoes double hydrogenation as described to obtain a compound of formula X'
Figure imgf000016_0003
Alternatively, in a process of the invention, a chiral reduction of the keto group in a compound of formula VI" may be conducted to obtain a compound of formula XI
Figure imgf000016_0004
The double bond and the BnO group of this compound of formula XI may then be hydrogenated to obtain the compound of formula I'".
In particular, the compound of formula VI' can be chirally reduced to the compound of formula XI'
Figure imgf000017_0001
which can then be hydrogenated to obtain the compound of formula I" In another process of the invention, a compound of formula VI" may be converted by the Noyori reduction, i.e. using the catalyst (R)- Ru(BINAP)Cl2]2-NEt3. to obtain the compound of formula I'". In particular, a compound of formula VI' can be reduced by this method to obtain a compound of formula I".
The starting material of formula I! is known, and may be prepared from s-malic acid of the formula
Figure imgf000017_0002
by reduction with BH3Mβ2*S followed by treatment with 5% NaBH4 to obtain a compound of the formula
Figure imgf000017_0003
followed by cyclization of this compound with CF3CO2H to obtain the γ-lactone of formula II.
Alternatively, the γ-lactone of formula II may be obtained from glucose as described in U.S. Patent 5,292,939, Hollingsworth, which is hereby incorporated by reference.
An imine of formula III' may be prepared by reacting 4-benzyloxy benzaldehyde with 4-fluoroaniline in a polar organic solvent such as isopropanol at about room temperature. Other imines of the formula III may be prepared in a similar manner, by reacting the appropriate benzaldehyde derivatives and the appropriate aniline derivatives in isopropanol at room temperature for 2 to 3 hours and filtering the reaction mixture to give the product as a solid.
An enolether of the formula E' may be prepared by reacting 4-fluoro-acetophenone (which is a -known compound or may be prepared by known methods) in a solution of lithium diisopropylamide in a polar organic solvent such THF at a temperature in the range of about -30°C to about -35°C, with quenching by addition of Mβ3SiCI, concentration and distillation to obtain the enolether product. Other enolethers of formula E may be prepared in a similar manner.
The following examples illustrate the process of this invention:
Example 1
H
Figure imgf000018_0001
To a 5-liter 3 neck flask equipped with a mechanical stirrer, thermometer and addition funnel were added 500 mL of THF, 400 mL of DMPU and 120 mL (0.92 mol) of diisopropylamine. To the cooled mixture at -40 to -45°C was added dropwise 368 mL (0.92 mol) of 2.5 M n-BuLi hexane solution. After 20 minutes, 47 g (0.46 mol) of lactone 3 diluted in 250 mL of THF was introduced and the reaction was agitated at -40 to -45°C for 2 hr. While agitating, 100 g (0.328 mol) of imine was dissolved in 1 liter of DMF and then was added dropwise through the addition funnel into the reaction mixture at -40 to -45°C (30 min.). The reaction was maintained at -25 to -30°C for 14 to 18 hrs and warmed to -13 to -17°C for another 4 hrs as followed by HPLC. 14 g of LiCI was dissolved in 400 mL DMF in a 500 mL flask and added into the reaction mixture. After another 2 hrs at -15°C, 200 mL of HOAc was added to quench the reaction.
The reaction mixture was poured slowly into a 10-liter extractor containing 2 liters of 3 N HCI, 1 liter ice and 2.5 liters of EtOAc. The mixture was stirred for 15 min. and separated into layers. The aqueous layer was extracted with 1.0 liter and then with 0.5 liter of EtOAc. The combined organic layers were washed with 4 X 2 liter brine, concentrated, and 250 mL toluene was added to crystallize the trans lactam 4. The solid was filtered and dried at 50°C to give 85.5 g (64% yield) lactam 4. Mp: 119-120°C. "<H NMR (CDCI3) 7.38 (m, 5H), 7.22 (m, 4H), 6.90 (m, 4H), 5.04 (d, J=2.0, 1 H), 5.02 (s, 2H), 4.21 (m, 1 H), 3.70 (m, 1 H), 3.6 (m,1 H), 3.52 (d, J=5.0, 1 H), 3.15 (dd, J=5.2, 2.0Hz), 2.85 (t, J=5.3, 1 H). 13C NMR (CDCI3) 165.5, 160.7, 159.0, 157.5, 136.7, 133.6, 133.5, 129.3, 128.7, 128.2, 127.6, 127.4, 118.8, 118.6, 116.0, 115.5, 70.1 , 69.5, 62.9, 56.8. HRMS: 408.1619 (MH+); Calc'd: 408.1611. [a] ??????-69.78 (c=0.121 , THF). Anal.Calc'd for C24H23FNO4: C, 70.75; H, 5.44; N, 3.44. Found: C, 70.57; H, 5.56; N, 3.41.
Example 2
Figure imgf000019_0001
To a 2 liter 3-neck flask equipped with a mechanical stirrer, thermometer and addition funnel were added sequentially 100 g (0.246 mmol) of lactam 4 and 800 mL of CH3CN. The mixture was cooled to 10°C with an ice bath. 63 g (0.295 mmol) of Nalθ4 was dissolved in 800 mL of water in a 1 liter flask and transfered into the addition funnel. The Nalθ4 solution was added into the reaction mixture at such a rate to maintain the temperature below 20°C (20 min.). After addition, the reaction was warmed to room temperature (r.t.) and stirred for 1 to 2 hrs as followed by NMR. The reaction was quenched into a 6 liter extractor containing 1.5 liters of ice-brine and 1.5 liters of toluene. The layers were stirred, separated and the aqueous layer was extracted with 500 mL of toluene. The combined organic layer was washed with 2 X 500 mL brine and concentrated to about 500 mL for the next reaction. MS: 376( MH+), 265, 239. 1H NMR (CDCI3) 9.82 (d, J=1.3Hz, 1 H), 7.31 (m, 5H), 7.17 (m, 4H), 6.88 (m, 4H), 5.32 (d, J=2.4H2, 1 H), 4.98 (s, 2H), 4.15 (dd, J=2.4, 1.3Hz, 1 H). Example 3
Figure imgf000020_0001
To a 1 liter 3-neck flask equipped with a mechanical stirrer, thermometer and addition funnel were added at r.t. a solution of 100 g (0.267mmol) of aldehyde 5 (from Example 2) in 500 mL of toluene and 32 mL (0.267 mmol) of BF3«etherate. The mixture was cooled to -30°C with a dry-ice bath. To the cooled mixture was added 56 g (0.267 mmol) of enolether dropwise. The aldol reaction is completed in 5 min. To another 5 liter extractor were added 1 liter of saturated NaHC03 solution, 2 liters of t-BuOMe, and 150 mL of hydrogen peroxide (30%). This quench solution was then cooled to 0°C with an ice bath. The aldol mixture was added dropwise into the quench solution at 0°C. The quenched mixture was allowed to warm to 15 to 20°C and the layers were separated. The aqueous layer was extracted with 1 liter toluene. The combined organic layer was washed with 2 X 500 mL and concentrated to about 1 liter for dehydration.
To the 1 liter toluene solution of aldol product obtained above were added 200 g of molecular sieves and 25 g (0.133 mmol) of p- toluenesulfonic acid monohydrate. This mixture was heated to 40 to 50°C and monitored by NMR (2 to 4 hrs.). The reaction was cooled to 0°C and filtered through a pad of MgSθ4 and then 100 g silica gel. The filtrate was concentrated for the next step. Alternatively, the concentrated solution was added to 400 mL of heptane to precipitate the double bond product (99 g, 7.5% overall yields). MS: 496 (MH+), 359, 305, 238. 1H NMR 8.01 (dd, J=8.5, 5.5Hz, 1H), 7.40 (m, 7H), 7.30 (m, 6H), 7.18 (m, 2H), 7.22 (d, J=8.6, 1 H), 6.98 (t, J=8.5Hz, 1 H), 5.08 (s, 2H), 4.88 (d, J=2.4, 1 H), 4.00 (m, 1 H). Example 4
Figure imgf000021_0001
To a 1 liter Parr pressure bottle were added 0.8 g of Palladium on carbon (10%), 1.6 g (19.0 mmol) of NaHC03, 16 g (32.3 mmol) of compound 6A in 80 mL of EtOAc and 80 mL of CH3OH. The bottle was shaken under 30 psi of hydrogen pressure for 2 to 3 hrs as followed by TLC and HPLC. The reaction mixture was filtered through a pad of celite and washed with 200 mL toluene. The filtrate was washed in a 1 liter extractor with 200 mL brine and 2 mL of 3 N HCI. After separation of the layers, the organic layer was washed with 2 X 200 mL brine. Concentration gave 11.8 g (90% yield) of compound 8.
(The reaction also could be carried out as follows: A mixture of 1 g of compound 6A in 10 mL of EtOAc, 1 mL of water, and 0.5 (w/w)% of Pd/C (wet) was shaken under 25 psi of H2 for ca. 4 hrs. The mixture was filtered through celite and washed with toluene. Concentration gave compound 8.
MS: 408 (MH+), 297. 1H NMR (CDCI3) 7.95 (dd, J=8.6, 5.5Hz, 2H), 7.13-7.22 (m, 4H), 7.09 (t, J=8.6, 2H), 6.91 (t, J=8.6, 2H), 6.80 (d, J=8.6Hz, 2H), 4.65 (d, J=2.1. 1H), 3.26 (m, 1 H), 2.33 (s, 1 H), 2.25 (m, 1 H). 13c (CDCI3) 197.7, 167.7, 164.5, 160.7, 157.5, 156.3, 133.8, 133.0, 130.9, 130.7, 129.2, 127.5, 118.6, 118.5, 116.2, 116.1 , 116.0, 115.8, 115.7, 61.3, 59.7, 35.6, 23.3. Anal. Calc'd. for C24Hi9NF203'1/2 H20: C, 69.75; H, 4.47; N, 2.95; F, 9.11. Found: C, 69.23; H, 4.80; N, 3.36; F, 9.13. Example 5
Figure imgf000022_0001
The chiral catalyst was made following the standard procedure: trimethylboroxine (28 mg, 0.22 mmol) was added into a solution of diphenylprolinol (75 mg, 0.3 mmol) in toluene (5ml) and the resultant solution was heated until refluxing. Toluene was distilled and another 5 ml of toluene was added and distilled out. The residue was used directly in the following reaction. To a 50 mL oven-dried flask with a magnetic stirrer were added
2.4 g (5.9 mmol) of compound 8, 10 mL CH2CI2, and 0.62 g (3.0 mmol) of bistrimethylsilyl urea (BSU). After 0.5 hr, the reaction was filtered directly into another 50 mL oven-dried flask containing 0.05 eq. of the chiral catalyst at -20°C. To this was added 2.3 mL (4.7 mmol) of 2 N BH3«Mβ2S. The reaction was stirred at -15 to -20°C and monitored by TLC and HPLC (3 to 5 hrs). 10 mL methanol/HCI was added, followed by concentration. Water and t-BuOMe were added to the residue and it was extracted with t-BuOMe (x2) to give a crude product solution. Concentration of t-BuOMe lead to the recovery of >50% catalyst as the HCI salt after filtration. Crystallization of crude product from lsopropanol/H2θ afforded 1.9 g of compound 8A. 1H NMR(DMSO) 9.54 (s, 1 H), 7.32 (dd, J=8.3, 5.7Hz, 2H), 7.21 (m, 4H), 7.35 (m, 4H), 6.77 (d, J=8.3Hz, 2H), 5.3 (d, J=4.6Hz, 1 H), 4.82 (d, J=2.1 Hz, 1 H), 4.50 (m, 1 H), 3.10 (m, 1 H), 1 ,70-1.9 (m, 4H). ">3C NMR(DMSO) 167.4, 162.3, 159.9, 159.3, 157.5, 156.9, 142.3, 142.3, 134.1 , 134.0, 128.0, 127.7, 127.6, 118.4, 118.3, 116.0, 115.8, 114.9, 114.7, 71.2, 59.7, 59.5, 36.5; 24.6. Example 6
Figure imgf000023_0001
The crude compound 6A, generated from dehydration step from 80 mmol of aldol condensation product, was dissolved in 120 ml of CH2CI2 to which 2.2g (2.4 mmol) of the catalyst was added. The mixture was subjected hydrogenation at 60 psi for 18 hr. Concentration of the reaction gave a residue of the product, which was separated by column with hexane and EtOAc (90:10) to give 27.5 g pure product, 71 % from aldol condensation product as starting material. 1H NMR (CDCI3) 7.98 (dd, J=8.5, 5.5Hz, 1 H), 7.41 (m, 5H), 7.25 (m, 4H), 7.12 (t, J=8.5, 2H), 6.55 (m, 4H), 5.04 (s, 2H), 4.68 (d, J=2.1 , 1 H), 3.65 (m, 1 H), 3.28 (m, 1 H), 3.16 (m, 1 H), 2.40 (m, 1 H), 2.28 (m, 1 H).
Example 7
Figure imgf000023_0002
To a 250 mL oven-dried flask with a magnetic stirrer were added 6.2 g (12.5 mmol) of compound 6B and 60 mL of CH2CI2. To the resulting solution at -20°C were added sequentially 0.1 equivalent of the chiral catalyst and 6.3 mL (12.5 mmol) of 2.0 N BH3»(CH3)2S over 2 h. The reaction was allowed to warm to 0°C, it was stirred at that temperature for 1 h and quenched with CH3OH. The quenched solution was concentrated and extracted with C^Ctø. The organic layer was concentrated and the residue was recrystallized from EtOAc and hexanes to give 4.1 g (70%) of 8B. The e.e. was determined by HPLC and found to be 93%. 1H NMR (CDCI3): δ 7.45-7.15 (m, 11 H), 7.00-6.80 (m, 6H), 4.98 (s, 2H), 4.70-4.60 (m, 1 H), 4.50 (d, 1 H), 3.05-2.97 (m, 1 H), 2.20-2.10 (m, 1 H), 1.95-1.75 (m, 4H).
Example 8
Figure imgf000024_0001
To a flask were added Pd-C (10%) (1g, 5% by w/w), ammonium bicarbonate (11.4 g, 181 mmole), compound 8B (18.1 g, 36.3 mmole) and CH3OH (250 mL) carefully at r.t. under N2. HOAc was added to adjust the pH to 3-5 and the resultant mixture was heated at 45 to 55°C until the reaction finished as determined by TLC (about 2-3hr). During the reaction, the pH was controlled in the range of 3-5 by adding HOAc. The reaction was filtered and the solvent evaporated. The residue was dissolved in t-BuOMe and washed with water. After drying over Na2S04 and evaporating the solvent, the product was purified by recrystallization in t-BuOMe/heptane and CH3OH/water to give 11.75 g (79%). 1H NMR (DMSO): 9.54 (s, 1 H), 7.32 (dd, J=8.3, 5.7Hz, 2H), 7.21 (m, 4H), 7.35 (m, 4H), 6.77 (d, J=8.3Hz, 2H), 5.3 (d, J=4.6Hz, 1 H), 4.82 (d, J=2.1 Hz, 1H), 4.50 (m, 1 H), 3.10 (m, 1 H), 1 ,70-1.9 (m, 4H). 13C NMR (DMSO) 167.4, 162.3, 159.9, 159.3, 157.5, 156.9, 142.3, 142.3, 134.1 , 134.0, 128.0,
127.7, 127.6, 118.4, 118.3, 116.0, 115.8, 114.9, 114.7, 71.2, 59.7, 59.5, 36.5, 24.6.
Example 9
Figure imgf000024_0002
(Cyclooctadienyl)ruthenium dichloride (10? mg, 0.38 mmol) and (R)-2,2'-bis)diphenylphosphino)-1 ,1,-binaphthyl (BINAP) (250 mg, 0.40 mmol) were placed in a flask and connected to Schlenck apparatus with another flask at the opposite end. The entire apparatus was evacuated, then filled with N2. Toluene (10 mL) and EtβN (1 mL), after deoxygenation several times, was charged into the lower flask, which was then heated to 140-145°C for 4 h. After cooling to r.t., red solid precipitated out of solution. The solid was filtered and washed with degased toluene inside of the apparatus under N2. The entire apparatus was evacuated and the solid was dried.
Compound 6A (50 mg, 0.1 mmol), the catalyst, [(R)- Ru(BINAP)Cl2]2-NEt3, prepared above (<10 mg, <0.01 mmol) and CH3OH (50 mL) with 1 drop of 2N HCI were charged in an autoclave under N2. The reaction was subjected to 850 psi H2 at 80°C for 48 h. Major product (I") was found and matched in TLC and HPLC profile with the product of Example 5.
Example 10 n
Figure imgf000025_0001
To a mixture of 300 mg (0.61 mmol) of 6A and 0.1 equivalent of the chiral catalyst in 5 mL of CH2CI2 at -15°C, 0.21 mL (0.4 mmol) of 2.0 N BH3*(CH3)2S was added dropwise over 5 min. The reaction was allowed to warm to 0°C, it was stirred for 45 min. and quenched with CH3OH. Concentration, followed by chromatography gave compound XI. The e.e. was determined to be 75%. 1H NMR (CDCI3): δ 7.55-6.82 (m, 18H), 5.95 (d, 1 H), 5.15 (d, 1 H), 4.98 (s, 2H), 4.65 (d, 1H), 3.65 (d, 1 H).

Claims

We Claim:
A process for producing a compound of the formula
Figure imgf000026_0001
wherein:
R-i , R2 and R3 are independently selected from the group consisting of:
(a) H;
(b) halo;
(c) -OR5, wherein: R5 is selected from the group consisting of H, Ci to Cβ alkyl, aryl, aralkyl, heteroaryl, C2 to Cβ alkynyl, C3 to C7 cycloalkyl,
C3 to C7 cycloalkenyl and -C(0)R6; Re is selected from the group consisting of Ci to Cβ alkyl, aryl and -OR7; and R7 is Ci to Cβ'alkyl or aryl; and
(d) -C(0)R8, wherein: Re is selected from the group consisting of Ci to Cβ alkyl, aryl, heteroaryl, aralkyl, cycloalkyl, -ORg and -N(Rιo)2; P-9 is selected from the group consisting of Ci to Cβ alkyl and aryl; and each R-JO is independently selected from the group consisting of H, Ci to CQ alkyl and aryl; comprising (a) reacting lactone of formula II
Figure imgf000026_0002
with an imine of formula III
Figure imgf000026_0003
in the presence of a base and optionally in the presence of a cyclization promoter to obtain a chiral diol of formula IV
Figure imgf000027_0001
(b) oxidizing the chiral diol of formula IV to the corresponding aldehyde of formula V
Figure imgf000027_0002
(c) condensing the aldehyde of formula V with an enolether of the formula E
Figure imgf000027_0003
followed by dehydration to obtain a compound of formula VI
Figure imgf000027_0004
(d) hydrogenating a compound of formula VI to form a compound of formula VII
Figure imgf000027_0005
(e) conducting a chiral catalytic reduction of the compound of formula VII to obtain a compound of formula I; (f) optionally, when any of R-|, R2 or R3 is a benzyloxy or alkoxy group, converting said benzyloxy or alkoxy group to a hydroxy group to obtain a compound of formula I.
2. A process according to claim 1 for producing the compound of the formula
Figure imgf000028_0001
comprising
(a) reacting lactone of formula II
Figure imgf000028_0002
with an imine of formula III'
Figure imgf000028_0003
in the presence of a base and optionally in the presence of a cyclization promoter to obtain a chiral diol of formula IV
Figure imgf000028_0004
(b) oxidizing the chiral diol of formula IV to the corresponding aldehyde of formula V
Figure imgf000029_0001
(c) condensing the aldehyde of formula V with an enolether of the formula E'
Figure imgf000029_0002
followed by dehydration to obtain a compound of formula VI'
Figure imgf000029_0003
(d) hydrogenating a compound of formula VI' to form a compound of formula VII'
Figure imgf000029_0004
(e) conducting a chiral catalytic reduction of the compound of formula VII' and a chiral catalyst of the formula
Figure imgf000029_0005
to obtain a compound of formula I'
Figure imgf000030_0001
(f) debenzylating the compound of formula I'.
A process for the preparation of a compound of the formula
Figure imgf000030_0002
wherein Ri and R2 are independently selected from the group consisting of:
(a) H;
(b) halo; (c) -OR5, wherein: R5 is selected from the group consisting of
H, Ci to Cβ alkyl, aryl, aralkyl, heteroaryl, C2 to Cβ alkynyl, C3 to C7 cycloalkyl, C3 to C7 cycloalkenyl and -C(0)R6; Re is selected from the group consisting of Ci to Ce alkyl, aryl and -OR7; and R7 is Ci to Cβ alkyl or aryl; and (d) -C(0)R8, wherein: Re is selected from the group consisting of Ci to Cβ alkyl, aryl, heteroaryl, aralkyl, cycloalkyl, -OR9 and -N(R-ιrj)2; R9 is selected from the group consisting of Ci to Cβ alkyl and aryl; and each R10 is independently selected from the group consisting of H, Ci to Cβ alkyl and aryl; comprising reacting a lactone of the formula
Figure imgf000030_0003
with an imine of the formula
Figure imgf000031_0001
wherein Ri and R2 are as defined above.
4. A process of claim 3 for preparing a compound of the formula
Figure imgf000031_0002
which comprises reacting a compound of the formula
Figure imgf000031_0003
with a compound of the formula
Figure imgf000031_0004
5. A compound of the formula
Figure imgf000031_0005
wherein Ri and R2 are independently selected from the group- consisting of:
(a) H;
(b) halo; (c) -OR5, wherein: R5 is selected from the group consisting of H, Ci to Cβ alkyl, aryl, aralkyl, heteroaryl, C2 to Cβ alkynyl, C3 to C7 cycloalkyl, C3 to C7 cycloalkβnyl and -C(0)R6; Re is selected from the group consisting of Ci to Cβ alkyl, aryl and -OR7; and R7 is C-i to Cβ alkyl or aryl; and
(d) -C(0)R8, wherein: Re is selected from the group consisting of Ci to Cβ alkyl, aryl, heteroaryl, aralkyl, cycloalkyl, -ORg and -N(R-ιo)2; Rg is selected from the group consisting of Ci to Cβ alkyl and aryl; and each R10 is independently selected from the group consisting of H, Ci to Cβ alkyl and aryl.
6. A compound according to claim 5 of the formula
Figure imgf000032_0001
7. A process for preparing a compound of the formula V
Figure imgf000032_0002
wherein Ri and R2 are independently selected from the group consisting of:
(a) H; (b) halo;
(c) -OR5, wherein: R5 is selected from the group consisting of H, Ci to Cβ alkyl, aryl, aralkyl, heteroaryl, C2 to Cβ alkynyl, C3 to C7 cycloalkyl, C3 to C7 cycloalkenyl and -C(0)R6; Re is selected from the group consisting of Ci to Cβ alkyl, aryl and -OR7; and R7 is Ci to Cβ alkyl or aryl; and
(d) -C(0)Rβ, wherein: Re is selected from the group consisting of Ci to Cβ alkyl, aryl, heteroaryl, aralkyl, cycloalkyl, -ORg and -N(R-ιo)2; R9 is selected from the group consisting of C-) to Cβ alkyl and aryl; and each R10 is independently selected from the group consisting of H, Ci to Cβ alkyl and aryl; comprising oxidizing a chiral diol of formula IV
Figure imgf000033_0001
wherein Ri and R2 are as defined above.
8. A compound of the formula
Figure imgf000033_0002
9. A process for preparing a compound of formula VI
Figure imgf000033_0003
wherein R-i , R2 and R3 are independently selected from the group consisting of: (a) H; (b) halo; (c) -OR5, wherein: R5 is selected from the group consisting of H, Ci to Cβ alkyl, aryl, aralkyl, heteroaryl, C2 to Cβ alkynyl, C3 to C7 cycloalkyl, C3 to C7 cycloalkenyl and -C(0)R6; Re is selected from the group consisting of Ci to Cβ alkyl, aryl and -OR7; and R7 is Ci to Cβ alkyl or aryl; and
(d) -C(0)Rβ, wherein: Re is selected from the group consisting of Ci to Cβ alkyl, aryl, heteroaryl, aralkyl, cycloalkyl, -ORg and -N(Rιo)2; R9 is selected from the group consisting of Ci to Cβ alkyl and aryl; and each R10 is independently selected from the group consisting of H, Ci to Cβ alkyl and aryl; comprising condensing an aldehyde of formula V
Figure imgf000034_0001
wherein Ri and R2 are as defined above, with an enolether of the formula E
Figure imgf000034_0002
wherein R3 is as defined above, followed by dehydration.
10. A compound of the formula
Figure imgf000034_0003
wherein Ri , R2 and R3 are independently selected from the group consisting of:
(a) H;
(b) halo; (c) -OR5, wherein: R5 is selected from the group consisting of H, Ci to Cβ alkyl, aryl, aralkyl, heteroaryl, C2 to Cβ alkynyl, C3 to C7 cycloalkyl, C3 to C7 cycloalkenyl and -C(0)R6; Re is selected from the group consisting of Ci to Cβ alkyl, aryl and -OR7; and R7 is Ci to Cβ alkyl or aryl; and
(d) -C(0)R8, wherein: Re is selected from the group consisting of Ci to Cβ alkyl, aryl, heteroaryl, aralkyl, cycloalkyl, -ORg and -N(Rιo)2; Rg is selected from the group consisting of Ci to Cβ alkyl and aryl; and each R10 is independently selected from the group consisting of H, Ci to Cβ alkyl and aryl.
11. A compound according to claim 10 of the formula
Figure imgf000035_0001
12. A process for preparing a compound of the formula VII
wherein Ri , R2 and R3 are independently selected from the group consisting of:
(a) H; (b) halo;
(c) -OR5, wherein: R5 is selected from the group consisting of H, Ci to Cβ alkyl, aryl, aralkyl, heteroaryl, C2 to Cβ alkynyl, C3 to C7 cycloalkyl, C3 to C7 cycloalkenyl and -C(0)R6; Re is selected from the group consisting of Ci to Cβ alkyl, aryl and -OR7; and R7 is Ci to Cβ alkyl or aryl; and
(d) -C(0)Rs, wherein: Re is selected from the group consisting of Ci to Cβ alkyl, aryl, heteroaryl, aralkyl, cycloalkyl, -ORg and -N(Rιo)2; R9 is selected from the group consisting of Ci to Cβ alkyl and aryl; and each
R10 is independently selected from the group consisting of H, Ci to Cβ alkyl and aryl; comprising hydrogenating a compound of formula VI
Figure imgf000036_0001
13. A process for preparing a compound of the formula X
Figure imgf000036_0002
wherein R2 and R3 are independently selected from the group consisting of: (a) H;
(b) halo;
(c) -OR5, wherein: R5 is selected from the group consisting of H, Ci to Cβ alkyl, aryl, aralkyl, heteroaryl, C2 to Cβ alkynyl, C3 to C7 cycloalkyl, C3 to C7 cycloalkenyl and -C(0)R6; Rε is selected from the group consisting of Ci to Cβ alkyl, aryl and -OR7; and R7 is Ci to Cβ alkyl or aryl; and
(d) -C(0)Rβ, wherein: Re is selected from the group consisting of Ci to Cβ alkyl, aryl, heteroaryl, aralkyl, cycloalkyl, -ORg and -N(Rιrj)2; Rg is selected from the group consisting of Ci to Cβ alkyl and aryl; and each R10 is independently selected from the group consisting of H, Ci to Cβ alkyl and aryl; comprising hydrogenating a compound of the formula VI"
Figure imgf000037_0001
14. A process for preparing a compound of the formula XI
Figure imgf000037_0002
wherein R2 and R3 are independently selected from the group consisting of:
(a) H;
(b) halo; (c) -OR5, wherein: R5 is selected from the group consisting of
H, Ci to Cβ alkyl, aryl, aralkyl, heteroaryl, C2 to Cβ alkynyl, C3 to C7 cycloalkyl, C3 to C7 cycloalkenyl and -C(0)R6; Re is selected from the group consisting of Ci to Cβ alkyl, aryl and -OR7; and R7 is Ci to Cβ alkyl or aryl; and (d) -C(0)Rβ, wherein: Re is selected from the group consisting of Ci to Cβ alkyl, aryl, heteroaryl, aralkyl, cycloalkyl, -ORg and -N(Rιo)2; R9 is selected from the group consisting of Ci to Cβ alkyl and aryl; and each R10 is independently selected from the group consisting of H, Ci to Cβ alkyl and aryl; comprising chirally reducing the compound of formula VI"
Figure imgf000037_0003
PCT/US1997/009666 1996-05-31 1997-05-28 3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones WO1997045406A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
AT97928831T ATE226191T1 (en) 1996-05-31 1997-05-28 ENANTIOSELECTIVE SYNTHESIS OF AZETIDINONES BASED ON 3-HYDROXY-GAMMA-LACTONE
JP54307797A JP3155759B2 (en) 1996-05-31 1997-05-28 3-Hydroxy γ-lactone-based enantioselective synthesis of azetidinone
DK97928831T DK0906278T3 (en) 1996-05-31 1997-05-28 Enantiol selective synthesis of azetidinones based on 3-hydroxy-gamma-lactone
DE69716426T DE69716426T2 (en) 1996-05-31 1997-05-28 ENANTIOSELECTIVE SYNTHESIS OF AZETIDINONES BASED ON 3-HYDROXY GAMMA LACTONE
EP97928831A EP0906278B1 (en) 1996-05-31 1997-05-28 3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones
AU32994/97A AU3299497A (en) 1996-05-31 1997-05-28 3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones
CA002255662A CA2255662C (en) 1996-05-31 1997-05-28 3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/655,785 US5739321A (en) 1996-05-31 1996-05-31 3-hydroxy γ-lactone based enantionselective synthesis of azetidinones
US08/655,785 1996-05-31

Publications (1)

Publication Number Publication Date
WO1997045406A1 true WO1997045406A1 (en) 1997-12-04

Family

ID=24630339

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/009666 WO1997045406A1 (en) 1996-05-31 1997-05-28 3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones

Country Status (14)

Country Link
US (1) US5739321A (en)
EP (1) EP0906278B1 (en)
JP (1) JP3155759B2 (en)
AR (1) AR007314A1 (en)
AT (1) ATE226191T1 (en)
AU (1) AU3299497A (en)
CA (1) CA2255662C (en)
CO (1) CO4770966A1 (en)
DE (1) DE69716426T2 (en)
DK (1) DK0906278T3 (en)
ES (1) ES2185026T3 (en)
PT (1) PT906278E (en)
WO (1) WO1997045406A1 (en)
ZA (1) ZA974678B (en)

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002050027A1 (en) * 2000-12-21 2002-06-27 Aventis Pharma Deutschland Gmbh Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism
WO2004103370A1 (en) 2003-05-15 2004-12-02 Merck & Co., Inc. Method of treating atherosclerosis, dyslipidemias and related conditions and pharmaceutical compositions
WO2005009955A1 (en) * 2003-07-31 2005-02-03 Hetero Drugs Limited Ezetimibe polymorphs
US7067675B2 (en) 2003-11-24 2006-06-27 Hetero Drugs Limited Process for ezetimibe intermediate
US7176194B2 (en) 2002-06-19 2007-02-13 Sanofi-Aventis Deutschland Gmbh Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
US7176193B2 (en) 2002-06-19 2007-02-13 Sanofi-Aventis Deutschland Gmbh Acid-group-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
WO2007072088A1 (en) * 2005-12-20 2007-06-28 Richter Gedeon Nyrt. Process for the production of ezetimibe and intermediates used in this proces
WO2007108007A1 (en) * 2006-03-23 2007-09-27 Unichem Laboratories Limited A process for the preparation of ezetimibe via a novel intermediate
WO2007144780A2 (en) * 2006-03-29 2007-12-21 Medichem S.A. Processes for preparing ezetimibe and intermediate compounds useful for the preparation thereof
WO2008032338A2 (en) * 2006-09-11 2008-03-20 Manne Satyanarayana Reddy Improved process for the preparation of ezetimibe and its intermediates
US7470678B2 (en) 2002-07-05 2008-12-30 Astrazeneca Ab Diphenylazetidinone derivatives for treating disorders of the lipid metabolism
EP2128133A1 (en) * 2008-05-26 2009-12-02 Lek Pharmaceuticals D.D. Ezetimibe process and composition
US7671047B2 (en) 2002-06-19 2010-03-02 Sanofi-Aventis Deutschland Gmbh Cationically substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
US7678935B2 (en) 2007-06-22 2010-03-16 Sanofi-Aventis Deutschland Gmbh Esters of pentahydroxyhexylcarbamoyl alkanoic acids
WO2010097350A1 (en) * 2009-02-24 2010-09-02 Adamed Sp. Z O.O. A process for the preparation of an aldehyde beta-lactam compound
US7842684B2 (en) 2006-04-27 2010-11-30 Astrazeneca Ab Diphenylazetidinone derivatives possessing cholesterol absorption inhibitor activity
US7871998B2 (en) 2003-12-23 2011-01-18 Astrazeneca Ab Diphenylazetidinone derivatives possessing cholesterol absorption inhibitory activity
US7893048B2 (en) 2005-06-22 2011-02-22 Astrazeneca Ab 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
EP2332526A2 (en) 2005-10-21 2011-06-15 Novartis AG Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent
US8003636B2 (en) 2007-11-13 2011-08-23 Sanofi-Aventis Deutschland Gmbh Certain crystalline diphenylazetidinone hydrates, pharmaceutical compositions thereof and methods for their use
EP2399578A1 (en) 2005-05-17 2011-12-28 The Interthyr Corporation Methods and compositions for the treatment of autoimmune and inflammatory diseases associated with toll-like receptors
WO2012004382A1 (en) 2010-07-09 2012-01-12 Moehs Iberica S.L. New method for preparing ezetimibe
CN102477008A (en) * 2010-11-22 2012-05-30 沈阳药科大学 Method for synthesizing ezetimibe
WO2012076030A1 (en) * 2010-12-10 2012-06-14 Pharmathen S.A. Process for the preparation of intermediate compounds useful in the preparation of ezetimibe
CN103739537A (en) * 2013-12-24 2014-04-23 连云港恒运医药科技有限公司 New synthesis method of ezetimibe
CN104072398A (en) * 2014-07-03 2014-10-01 河南省科学院化学研究所有限公司 Method for synthesizing ezetimibe
CN107033051A (en) * 2017-06-08 2017-08-11 武汉励合生物医药科技有限公司 A kind of preparation method of ezetimibe
WO2017140251A1 (en) * 2016-02-19 2017-08-24 常州方楠医药技术有限公司 Method for preparing ezetimibe and intermediate compound thereof

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US5886171A (en) * 1996-05-31 1999-03-23 Schering Corporation 3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones
EP1137634B1 (en) * 1998-12-07 2005-06-15 Schering Corporation Process for the synthesis of azetidinones
US6207822B1 (en) 1998-12-07 2001-03-27 Schering Corporation Process for the synthesis of azetidinones
US20060287254A1 (en) * 2001-01-26 2006-12-21 Schering Corporation Use of substituted azetidinone compounds for the treatment of sitosterolemia
RS51449B (en) * 2001-01-26 2011-04-30 Schering Corporation Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
BRPI0208384B1 (en) 2001-03-28 2016-05-31 Merck Sharp & Dohme enantioselective synthesis of azetidinone intermediate compounds
DE60216300T2 (en) * 2001-09-21 2007-06-28 Schering Corp. TREATMENT OF XANTHOM BY AZETIDINONE DERIVATIVES AS AN INHIBITOR OF STEROL ABSORPTION
US20030204096A1 (en) * 2002-03-25 2003-10-30 Schering Corporation Enantioselective synthesis of azetidinone intermediate compounds
US7135556B2 (en) * 2002-07-19 2006-11-14 Schering Corporation NPC1L1 (NPC3) and methods of use thereof
JP5137228B2 (en) * 2003-03-07 2013-02-06 メルク・シャープ・アンド・ドーム・コーポレーション Substituted azetidinone compounds, substituted azetidinone formulations and their use for the treatment of hypercholesterolemia
DE602004018617D1 (en) * 2003-03-07 2009-02-05 Schering Corp SUBSTITUTED AZETIDINONE DERIVATIVES, THEIR PHARMACEUTICAL FORMULATIONS AND THEIR USE FOR THE TREATMENT OF HYPERCHOLESTEROLMIA
US7459442B2 (en) * 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
GB0329778D0 (en) * 2003-12-23 2004-01-28 Astrazeneca Ab Chemical compounds
MXPA06008124A (en) * 2004-01-16 2007-01-26 Merck & Co Inc Npc1l1 (npc3) and methods of identifying ligands thereof.
US20070244107A1 (en) * 2004-08-25 2007-10-18 Waters M Gerard Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions
US20060160785A1 (en) * 2004-12-03 2006-07-20 Judith Aronhime Ezetimibe polymorphs
US20060234996A1 (en) * 2005-04-14 2006-10-19 Itai Adin Novel crystalline form of ezetimibe and processes for the preparation thereof
WO2007001975A1 (en) * 2005-06-20 2007-01-04 Schering Corporation Piperidine derivatives useful as histamine h3 antagonists
AR054482A1 (en) * 2005-06-22 2007-06-27 Astrazeneca Ab DERIVATIVES OF AZETIDINONE FOR THE TREATMENT OF HYPERLIPIDEMIAS
US20070049748A1 (en) * 2005-08-26 2007-03-01 Uppala Venkata Bhaskara R Preparation of ezetimibe
CA2616058A1 (en) * 2005-09-08 2007-03-15 Vinod Kumar Kansal Processes for the preparation of (3r,4s)-4-((4-benzyloxy)phenyl)-1-(4-fluorophenyl)-3-((s)-3-(4-fluorophenyl)-3-hydroxypropyl)-2-azetidinone, an intermediate for the synthesis of ezetimibe
US20090227786A1 (en) * 2005-12-22 2009-09-10 Ana Gavalda I Escude Processes for preparing intermediate compounds useful for the preparation of ezetimibe
US7910698B2 (en) * 2006-02-24 2011-03-22 Schering Corporation NPC1L1 orthologues
WO2008027081A1 (en) * 2006-08-29 2008-03-06 Teva Pharmaceutical Industries Ltd. Processes for the purification of (3r,4s)-4-(4-hydroxy-protected-phenyl)-1-(4-fluorophenyl)-3-(4-fluorophenyl)-3-oxopropyl] azetidin-2-one
JP2010502702A (en) * 2006-09-05 2010-01-28 シェーリング コーポレイション Pharmaceutical composition for use in lipid management and therapeutic treatment of atherosclerosis and fatty liver
WO2008057336A2 (en) * 2006-11-02 2008-05-15 Merck & Co., Inc. Heterocyclyl-substituted anti-hypercholesterolemic compounds
JP2010529148A (en) * 2007-06-07 2010-08-26 テバ ファーマシューティカル インダストリーズ リミティド Reduction method for the production of ezetimibe
CZ305066B6 (en) * 2008-02-25 2015-04-22 Zentiva, K.S. Process for preparing (3R, 4S)-l-(4-fiuorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3- hydroxypropyl)]-4-(4-hydroxyphenyl)-2-azetidinone
CA2757722C (en) 2009-04-01 2018-05-22 Matrix Laboratories Ltd. Enzymatic process for the preparation of (s)-5-(4-fluoro-phenyl)-5-hydroxy- 1morpholin-4-yl-pentan-1-one, an intermediate of ezetimibe and further conversion to ezetimibe
US9040262B2 (en) 2010-05-04 2015-05-26 Codexis, Inc. Biocatalysts for ezetimibe synthesis
WO2012155932A1 (en) 2011-05-17 2012-11-22 Pharmathen S.A. Improved process for the preparation of ezetimibe
PL231215B1 (en) 2011-06-15 2019-02-28 Inst Chemii Organicznej Polskiej Akademii Nauk Process for the preparation of substituted azetidinones and intermediates for the synthesis thereof
CN103086938A (en) * 2011-10-28 2013-05-08 沈阳药科大学 Ezetimibe synthesis method
CN102531986A (en) * 2012-02-23 2012-07-04 苏州朗科生物技术有限公司 Preparation method for ezetimibe
CN103570574B (en) 2012-07-20 2016-04-13 中国科学院上海有机化学研究所 Intermediate used in a kind of synthetic method of ezetimibe and the method
CN103044305A (en) * 2013-01-24 2013-04-17 上海现代制药股份有限公司 Preparation method of ezetimibe intermediate
WO2015039675A1 (en) 2013-09-23 2015-03-26 Pharmathen S.A. Novel process for the preparation of ezetimibe intermediates
JP2016145173A (en) * 2015-02-09 2016-08-12 株式会社トクヤマ Method for producing (3r,4s)-1-(4-fluorophenyl)-[3(s)-hydroxy-3-(4-fluorophenyl)propyl]-(4-hydroxyphenyl)-2-azetidinone

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995008532A1 (en) * 1993-09-21 1995-03-30 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
WO1997016424A1 (en) * 1995-11-02 1997-05-09 Schering Corporation Process for preparing 1-(4-fluorophenyl)-3(r)-(3(s)-hydroxy-3-([phenyl or 4-fluorophenyl])-propyl)-4(s)-(4-hydroxyphenyl)-2-azetidinone

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995008532A1 (en) * 1993-09-21 1995-03-30 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
WO1997016424A1 (en) * 1995-11-02 1997-05-09 Schering Corporation Process for preparing 1-(4-fluorophenyl)-3(r)-(3(s)-hydroxy-3-([phenyl or 4-fluorophenyl])-propyl)-4(s)-(4-hydroxyphenyl)-2-azetidinone

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 109, no. 5, 1 August 1988, Columbus, Ohio, US; abstract no. 38139, I. PANFIL ET AL.: "An entry to the optically pure beta-lactam skeleton based on 1,3-dipolar cycloaddition of nitrones to 4,6-di-O-acetyl-2,3-dideoxy-D-threo-hex-2-enono-1,5-lactone" XP002041212 *
I. PANFIL ET AL.: "1,3-Dipolar cycloaddition of nitrone to sugar enlactones", TETRAHEDRON, vol. 47, no. 48, 1991, OXFORD G.B., pages 10087 - 10094, XP002041211 *
J. CARBOHYDR. CHEM., vol. 6, no. 3, 1987, pages 463 - 470 *

Cited By (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002050027A1 (en) * 2000-12-21 2002-06-27 Aventis Pharma Deutschland Gmbh Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism
US7674773B2 (en) 2000-12-21 2010-03-09 Sanofi-Aventis Deutschland Gmbh Diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use
US7488829B2 (en) 2000-12-21 2009-02-10 Sanofi-Aventis Deutschland Gmbh Diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use
US6992067B2 (en) 2000-12-21 2006-01-31 Aventis Pharma Deutschland Gmbh Diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use
US7388004B2 (en) 2002-06-19 2008-06-17 Sanofi-Aventis Deutschland Gmbh Acid-group-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
US7176193B2 (en) 2002-06-19 2007-02-13 Sanofi-Aventis Deutschland Gmbh Acid-group-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
US7671047B2 (en) 2002-06-19 2010-03-02 Sanofi-Aventis Deutschland Gmbh Cationically substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
US7176194B2 (en) 2002-06-19 2007-02-13 Sanofi-Aventis Deutschland Gmbh Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
US7579339B2 (en) 2002-06-19 2009-08-25 Sanofi-Aventis Deutschland Gmbh Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
US7390790B2 (en) 2002-06-19 2008-06-24 Sanofi-Aventis Deutschland Gmbh Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
US7407938B2 (en) 2002-06-19 2008-08-05 Sanofi-Aventis Deutschland Gmbh Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
US7470678B2 (en) 2002-07-05 2008-12-30 Astrazeneca Ab Diphenylazetidinone derivatives for treating disorders of the lipid metabolism
WO2004103370A1 (en) 2003-05-15 2004-12-02 Merck & Co., Inc. Method of treating atherosclerosis, dyslipidemias and related conditions and pharmaceutical compositions
EP2286816A1 (en) 2003-05-15 2011-02-23 Merck Sharp & Dohme (I.A.) Corp. Method of treating atherosclerosis, dyslipidemias and related conditions
EP2116244A1 (en) 2003-05-15 2009-11-11 Merck & Co., Inc. Method of treating atherosclerosis, dyslipidemias and related conditions
WO2005009955A1 (en) * 2003-07-31 2005-02-03 Hetero Drugs Limited Ezetimibe polymorphs
US7067675B2 (en) 2003-11-24 2006-06-27 Hetero Drugs Limited Process for ezetimibe intermediate
US7871998B2 (en) 2003-12-23 2011-01-18 Astrazeneca Ab Diphenylazetidinone derivatives possessing cholesterol absorption inhibitory activity
EP2399578A1 (en) 2005-05-17 2011-12-28 The Interthyr Corporation Methods and compositions for the treatment of autoimmune and inflammatory diseases associated with toll-like receptors
US7893048B2 (en) 2005-06-22 2011-02-22 Astrazeneca Ab 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
EP2332526A2 (en) 2005-10-21 2011-06-15 Novartis AG Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent
WO2007072088A1 (en) * 2005-12-20 2007-06-28 Richter Gedeon Nyrt. Process for the production of ezetimibe and intermediates used in this proces
EA014331B1 (en) * 2005-12-20 2010-10-29 Рихтер Гедеон Нирт. Process for the production of ezetimibe and intermediates used in this process
WO2007108007A1 (en) * 2006-03-23 2007-09-27 Unichem Laboratories Limited A process for the preparation of ezetimibe via a novel intermediate
WO2007144780A3 (en) * 2006-03-29 2008-04-17 Medichem Sa Processes for preparing ezetimibe and intermediate compounds useful for the preparation thereof
WO2007144780A2 (en) * 2006-03-29 2007-12-21 Medichem S.A. Processes for preparing ezetimibe and intermediate compounds useful for the preparation thereof
US7842684B2 (en) 2006-04-27 2010-11-30 Astrazeneca Ab Diphenylazetidinone derivatives possessing cholesterol absorption inhibitor activity
WO2008032338A2 (en) * 2006-09-11 2008-03-20 Manne Satyanarayana Reddy Improved process for the preparation of ezetimibe and its intermediates
WO2008032338A3 (en) * 2006-09-11 2009-10-15 Manne Satyanarayana Reddy Improved process for the preparation of ezetimibe and its intermediates
US7678935B2 (en) 2007-06-22 2010-03-16 Sanofi-Aventis Deutschland Gmbh Esters of pentahydroxyhexylcarbamoyl alkanoic acids
US8003636B2 (en) 2007-11-13 2011-08-23 Sanofi-Aventis Deutschland Gmbh Certain crystalline diphenylazetidinone hydrates, pharmaceutical compositions thereof and methods for their use
CN102066318A (en) * 2008-05-26 2011-05-18 力奇制药公司 Process for the preparation of ezetimibe and composition containing it
EP2128133A1 (en) * 2008-05-26 2009-12-02 Lek Pharmaceuticals D.D. Ezetimibe process and composition
WO2009150038A1 (en) * 2008-05-26 2009-12-17 Lek Pharmaceuticals D.D. Process for the preparation of ezetimibe and composition containing it
WO2010097350A1 (en) * 2009-02-24 2010-09-02 Adamed Sp. Z O.O. A process for the preparation of an aldehyde beta-lactam compound
WO2012004382A1 (en) 2010-07-09 2012-01-12 Moehs Iberica S.L. New method for preparing ezetimibe
CN102477008A (en) * 2010-11-22 2012-05-30 沈阳药科大学 Method for synthesizing ezetimibe
WO2012076030A1 (en) * 2010-12-10 2012-06-14 Pharmathen S.A. Process for the preparation of intermediate compounds useful in the preparation of ezetimibe
CN103739537A (en) * 2013-12-24 2014-04-23 连云港恒运医药科技有限公司 New synthesis method of ezetimibe
CN103739537B (en) * 2013-12-24 2015-05-20 连云港恒运医药科技有限公司 New synthesis method of ezetimibe
CN104072398A (en) * 2014-07-03 2014-10-01 河南省科学院化学研究所有限公司 Method for synthesizing ezetimibe
WO2017140251A1 (en) * 2016-02-19 2017-08-24 常州方楠医药技术有限公司 Method for preparing ezetimibe and intermediate compound thereof
CN107033051A (en) * 2017-06-08 2017-08-11 武汉励合生物医药科技有限公司 A kind of preparation method of ezetimibe

Also Published As

Publication number Publication date
ES2185026T3 (en) 2003-04-16
US5739321A (en) 1998-04-14
EP0906278B1 (en) 2002-10-16
AU3299497A (en) 1998-01-05
EP0906278A1 (en) 1999-04-07
JPH11511754A (en) 1999-10-12
DK0906278T3 (en) 2003-02-17
ZA974678B (en) 1997-11-28
AR007314A1 (en) 1999-10-27
PT906278E (en) 2003-01-31
CA2255662C (en) 2005-11-08
DE69716426D1 (en) 2002-11-21
JP3155759B2 (en) 2001-04-16
DE69716426T2 (en) 2003-08-14
CO4770966A1 (en) 1999-04-30
ATE226191T1 (en) 2002-11-15
CA2255662A1 (en) 1997-12-04

Similar Documents

Publication Publication Date Title
EP0906278B1 (en) 3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones
US6096883A (en) 3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones
US5856473A (en) Process for preparing 1-(4-fluorophenyl)-3(R)-(3(S)-hydroxy-3-( phenyl or 4-fluorophenyl!)-propyl)-4(S)-(4-hydroxyphenyl)-2-azetidinone
US20030225149A1 (en) Process for preparing highly functionalized gamma-butyrolactams and gamma-amino acids
EP1230240B1 (en) Process and intermediates for the preparation of imidazolidinone alpha v integrin antagonists
US6590102B1 (en) Process for producing piperidinecarbinols
KR100567941B1 (en) Method for producing -cis-3-hydroxy-1-methyl-4-2,4,6-trimethoxyphenyl-piperidine
JP2001504081A (en) Preparation of optically enriched 4-aryl-3-hydromethyl-substituted piperidines as intermediates for paroxetine synthesis
US6437136B2 (en) Process for the preparation of (−)cis-3-hydroxy-1-methyl-4-(2,4,6-trimethoxyphenyl)piperidine
KR0160136B1 (en) Process for the preparation of castanospermine
EP0911335B1 (en) Method for producing furopyridine derivatives and intermediate compounds
JPS6328423B2 (en)
KR890000419B1 (en) Process for production of encanide
JP3140698B2 (en) Production method and purification method of 4-hydroxy-2-pyrrolidinone
JP2002533325A (en) Process for producing aryl piperidine carbinol intermediates and derivatives
CZ305024B6 (en) Process for preparing quinoline carboxaldehyde derivatives and intermediates thereof
JP4267125B2 (en) Method for producing pyridine alcohol derivative
JP2786300B2 (en) Stereoselective process for producing optically active S, S- or R, R-β-amino alcohols
KR100532042B1 (en) Process for the preparation of n,n-substituted-7-amino-3,5-dihydroxy heptanoic acid derivatives
Sandelier et al. Desoxoprosopinine: A Model for the Total Asymmetric Synthesis of Prosopis Alkaloids
JPH0853414A (en) 4-amino-3-hydroxyphthalimidine and its production
WO1988001619A1 (en) 1&#39;-methyl-beta-lactam compounds and their production
JPH0633264B2 (en) Method for producing O-substituted teriliverin
JP2001348374A (en) Method for producing 2-pyrrolidone derivative
MXPA00006631A (en) Method for producing (-)cis-3-hydroxy-1-methyl-4- (2,4,6-trimethoxyphenyl)-piperidine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AU AZ BA BB BG BR BY CA CN CZ EE GE HU IL IS JP KG KR KZ LC LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK TJ TM TR TT UA UZ VN YU AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1997928831

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2255662

Country of ref document: CA

Ref document number: 2255662

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/A/1998/009905

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 1997 543077

Country of ref document: JP

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 1997928831

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1997928831

Country of ref document: EP